Company Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany.
The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.
It also develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors.
It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers.
The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014.
Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany.
| Country | Germany |
| Founded | 2000 |
| IPO Date | Sep 12, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 76 |
| CEO | Dr. Andreas Harstrick M.D. |
Contact Details
Address: Gottlieb-daimler-strasse 2 Mannheim, 2M 68165 Germany | |
| Phone | 49-621-560030 |
| Website | affimed.com |
Stock Details
| Ticker Symbol | AFMD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001608390 |
| CUSIP Number | N01045108 |
| ISIN Number | NL0015001ZQ0 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Andreas Harstrick M.D. | Interim Chief Executive Officer, Chief Medical Officer and Member of Management Board |
| Dr. Wolfgang Fischer Ph.D. | MD, Chief Operating Officer and Member of Management Board |
| Denise Mueller | Chief Business Officer and Member of Management Board |
| Prof. Melvyn Little | Founder and Consultant |
| Michael Wolf | Head of Finance and Administration |
| Alexander Fudukidis | Head of Investor Relations and Director of Investor Relations |
| Mary Beth Sandin | Vice President of Marketing and Communications |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 28, 2024 | 6-K | Report of foreign issuer |
| Mar 28, 2024 | 20-F | Annual and transition report of foreign private issuers |
| Mar 11, 2024 | 6-K | Report of foreign issuer |
| Mar 6, 2024 | 6-K | Report of foreign issuer |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 8, 2024 | 6-K | Report of foreign issuer |
| Jan 8, 2024 | 6-K | Report of foreign issuer |
| Dec 11, 2023 | 6-K | Report of foreign issuer |
| Nov 30, 2023 | 6-K | Report of foreign issuer |